New drug combo targets Hard-to-Treat thyroid cancer
NCT ID NCT01947023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that had a specific BRAF mutation and could not be removed by surgery. The main goal was to find the safest dose of lapatinib when given with dabrafenib, and to see how the drugs affect cancer-related proteins. The study is now complete but not yet published.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare, aggressive thyroid cancer: drug combo shows promise
- Immunotherapy cocktail takes on deadly thyroid cancer
- New drug combo offers hope for hard-to-treat thyroid cancer
- Can a cancer drug make radioactive iodine work again for thyroid tumors?
- Freezing and zapping: new combo therapy aims to ease bone cancer pain